Created at	Source	Raw Value	Validated value
Feb. 15, 2022, 4:30 p.m.	usa	Cohort 1: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28.;Cohort 1: GMT of neutralizing antibodies to Omicron (B.1.1.529) variant on D28;Cohort 1: Incidence and severity of solicited AEs from D0 to D7 after study vaccination.;Cohort 1: Incidence and severity of unsolicited AEs from D0 to D28 after study vaccination.;Cohort 2: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28.;Cohort 2: Incidence and severity of solicited AEs from D0 to D7 after study vaccination.;Cohort 2: Incidence and severity of unsolicited AEs from D0 to D28 after study vaccination.	Cohort 1: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28.;Cohort 1: GMT of neutralizing antibodies to Omicron (B.1.1.529) variant on D28;Cohort 1: Incidence and severity of solicited AEs from D0 to D7 after study vaccination.;Cohort 1: Incidence and severity of unsolicited AEs from D0 to D28 after study vaccination.;Cohort 2: GMT of neutralizing antibodies to Delta (B.1.617.2) variant on D28.;Cohort 2: Incidence and severity of solicited AEs from D0 to D7 after study vaccination.;Cohort 2: Incidence and severity of unsolicited AEs from D0 to D28 after study vaccination.